Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test

US States Cast In The Role Of ‘Laboratory For Health Policy Change’

As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.

Colorado Flag
• Source: Shutterstock

The concept of prescription drug affordability boards is being increasingly explored by US state lawmakers who have become frustrated at Washington's lack of progress in addressing drug pricing. Although the Biden administration succeeded in making it possible for the Medicare program to negotiate prices, the initiative applies only to a small number of medicines each year and does not include the costs borne by Americans with private health insurance.

Yet various efforts by state governments over the years to combat prescription drug costs have met with fierce pushback from...

More from Market Access

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

More from In Vivo